258TiP A phase II trial of loperamide (L) and granulocyte colony-stimulating factors (G-CSF) to improve sacituzumab govitecan (SG) tolerance in patients (pts) with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): PRIMED
| Autor: | Pérez-García, J.M., Cortes, M. Gion, Bueno, A. Martinez, Morales, S., Calvo-Martinez, L., Farre, X. González, Blanch, S., López-Barajas, I. Blancas, López-Miranda, E., Fazal-Salom, J., Lazaris, A., Shimizu, E., Castedo, S.P. Cortez, Borrego, M. Ruiz, Cortés, J., Cussac, A. Llombart |
|---|---|
| Zdroj: | In ESMO Open May 2023 8(1) Supplement 4 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|